EG24075A - Pharmaceutical suspension comprising nevirapine hemihydrate - Google Patents
Pharmaceutical suspension comprising nevirapine hemihydrateInfo
- Publication number
- EG24075A EG24075A EG98398A EG98398A EG24075A EG 24075 A EG24075 A EG 24075A EG 98398 A EG98398 A EG 98398A EG 98398 A EG98398 A EG 98398A EG 24075 A EG24075 A EG 24075A
- Authority
- EG
- Egypt
- Prior art keywords
- pharmaceutical suspension
- nevirapine hemihydrate
- nevirapine
- hemihydrate
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5680397P | 1997-08-25 | 1997-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
EG24075A true EG24075A (en) | 2008-05-11 |
Family
ID=22006658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EG98398A EG24075A (en) | 1997-08-25 | 1998-08-23 | Pharmaceutical suspension comprising nevirapine hemihydrate |
Country Status (38)
Country | Link |
---|---|
US (2) | US6172059B1 (ko) |
EP (1) | EP1019058B1 (ko) |
JP (1) | JP3472261B2 (ko) |
KR (1) | KR100426516B1 (ko) |
CN (1) | CN1197578C (ko) |
AR (2) | AR016869A1 (ko) |
AT (1) | ATE326971T1 (ko) |
AU (1) | AU742761B2 (ko) |
BG (1) | BG64337B1 (ko) |
BR (1) | BR9811994B1 (ko) |
CA (1) | CA2301646C (ko) |
CL (1) | CL2008003111A1 (ko) |
CO (1) | CO4970742A1 (ko) |
CY (1) | CY1105228T1 (ko) |
CZ (1) | CZ290667B6 (ko) |
DE (1) | DE69834655T2 (ko) |
DK (1) | DK1019058T3 (ko) |
EG (1) | EG24075A (ko) |
ES (1) | ES2265666T3 (ko) |
HK (1) | HK1027975A1 (ko) |
HR (1) | HRP980461B1 (ko) |
HU (1) | HU226063B1 (ko) |
ID (1) | ID21650A (ko) |
IL (1) | IL134185A (ko) |
MY (1) | MY122272A (ko) |
NO (1) | NO326226B1 (ko) |
NZ (1) | NZ503414A (ko) |
PE (1) | PE105799A1 (ko) |
PL (1) | PL192361B1 (ko) |
PT (1) | PT1019058E (ko) |
RS (1) | RS49808B (ko) |
RU (1) | RU2196584C2 (ko) |
SA (1) | SA98190680B1 (ko) |
TR (1) | TR200000490T2 (ko) |
TW (1) | TW450812B (ko) |
UA (1) | UA44370C2 (ko) |
WO (1) | WO1999009990A1 (ko) |
ZA (1) | ZA987623B (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092095A1 (en) * | 2001-05-11 | 2002-11-21 | Boehringer Ingelheim International Gmbh | Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine |
EP1504040A1 (en) * | 2002-04-23 | 2005-02-09 | Boehringer Ingelheim Pharmaceuticals Inc. | Method for reduction of residual organic solvent in carbomer |
AP2008004389A0 (en) * | 2005-08-31 | 2008-04-30 | Cipla Ltd | Pharmaceutical combinations containing lamivudine,stavudine,stavudine and navirapine |
WO2010006697A2 (en) * | 2008-06-30 | 2010-01-21 | Tibotec Pharmaceuticals | Powders for reconstitution |
CA2781014C (en) * | 2009-11-10 | 2018-07-31 | Wilna Liebenberg | Method for increasing the solubility of a transcriptase inhibitor composition |
DE112010004862T5 (de) * | 2009-12-17 | 2012-12-06 | North West University | Polymorphe Form von Nevirapin und deren Herstellung |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5366972A (en) * | 1989-04-20 | 1994-11-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection |
CA2030056C (en) * | 1989-11-17 | 1995-10-17 | Karl D. Hargrave | 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection |
US5571912A (en) * | 1990-10-19 | 1996-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines |
DE4403311C1 (de) * | 1994-02-03 | 1995-04-20 | Boehringer Ingelheim Kg | Verfahren zur Herstellung von Nevirapine (11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4-diazepin]-6-on) |
-
1998
- 1998-08-11 AU AU87771/98A patent/AU742761B2/en not_active Ceased
- 1998-08-11 HU HU0003093A patent/HU226063B1/hu not_active IP Right Cessation
- 1998-08-11 CZ CZ2000694A patent/CZ290667B6/cs not_active IP Right Cessation
- 1998-08-11 WO PCT/US1998/016581 patent/WO1999009990A1/en active IP Right Grant
- 1998-08-11 PT PT98939312T patent/PT1019058E/pt unknown
- 1998-08-11 IL IL13418598A patent/IL134185A/xx not_active IP Right Cessation
- 1998-08-11 ES ES98939312T patent/ES2265666T3/es not_active Expired - Lifetime
- 1998-08-11 JP JP2000507380A patent/JP3472261B2/ja not_active Expired - Fee Related
- 1998-08-11 RU RU2000107825/14A patent/RU2196584C2/ru not_active IP Right Cessation
- 1998-08-11 US US09/131,829 patent/US6172059B1/en not_active Expired - Lifetime
- 1998-08-11 PL PL338828A patent/PL192361B1/pl unknown
- 1998-08-11 UA UA2000031668A patent/UA44370C2/uk unknown
- 1998-08-11 TR TR2000/00490T patent/TR200000490T2/xx unknown
- 1998-08-11 RS YUP-98/00A patent/RS49808B/sr unknown
- 1998-08-11 DE DE69834655T patent/DE69834655T2/de not_active Expired - Lifetime
- 1998-08-11 CN CNB988084899A patent/CN1197578C/zh not_active Expired - Fee Related
- 1998-08-11 PE PE1998000718A patent/PE105799A1/es not_active Application Discontinuation
- 1998-08-11 KR KR10-2000-7001889A patent/KR100426516B1/ko not_active IP Right Cessation
- 1998-08-11 AT AT98939312T patent/ATE326971T1/de active
- 1998-08-11 DK DK98939312T patent/DK1019058T3/da active
- 1998-08-11 CA CA002301646A patent/CA2301646C/en not_active Expired - Fee Related
- 1998-08-11 BR BRPI9811994-0B1A patent/BR9811994B1/pt not_active IP Right Cessation
- 1998-08-11 EP EP98939312A patent/EP1019058B1/en not_active Expired - Lifetime
- 1998-08-11 NZ NZ503414A patent/NZ503414A/xx not_active IP Right Cessation
- 1998-08-21 MY MYPI98003819A patent/MY122272A/en unknown
- 1998-08-23 EG EG98398A patent/EG24075A/xx active
- 1998-08-24 CO CO98048247A patent/CO4970742A1/es unknown
- 1998-08-24 TW TW087113878A patent/TW450812B/zh not_active IP Right Cessation
- 1998-08-24 ZA ZA9807623A patent/ZA987623B/xx unknown
- 1998-08-24 HR HR980461A patent/HRP980461B1/xx not_active IP Right Cessation
- 1998-08-24 ID IDP981156A patent/ID21650A/id unknown
- 1998-08-25 AR ARP980104200A patent/AR016869A1/es not_active Ceased/Invalidation/Refusal/Rejection/Nullification
- 1998-11-01 SA SA98190680A patent/SA98190680B1/ar unknown
-
2000
- 2000-02-07 BG BG104133A patent/BG64337B1/bg active Active
- 2000-02-24 NO NO20000906A patent/NO326226B1/no not_active IP Right Cessation
- 2000-03-02 US US09/517,564 patent/US6255481B1/en not_active Expired - Lifetime
- 2000-11-20 HK HK00107393A patent/HK1027975A1/xx not_active IP Right Cessation
-
2006
- 2006-08-11 CY CY20061101147T patent/CY1105228T1/el unknown
-
2008
- 2008-10-21 CL CL2008003111A patent/CL2008003111A1/es unknown
-
2011
- 2011-10-14 AR ARP110103815A patent/AR083451A2/es active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL340337A1 (en) | Drugs | |
GB9706089D0 (en) | Pharmaceutical composition | |
GB9700504D0 (en) | Pharmaceutical compounds | |
SG76535A1 (en) | Pharmaceutical agents | |
GB9726563D0 (en) | Novel pharmaceutical | |
GB9726566D0 (en) | Novel pharmaceutical | |
GB9815532D0 (en) | Pharmaceutical suspension formulation | |
EG23694A (en) | Novel pharmaceutical | |
EP1003495A4 (en) | PHARMACEUTICAL COMPOUNDS | |
GB9716244D0 (en) | Pharmaceutical compounds | |
GB9717444D0 (en) | Pharmaceutical composition | |
ZA982073B (en) | Pharmaceutical preparation | |
HUP0002455A3 (en) | Gastric-retained pharmaceutical composition | |
GB9717428D0 (en) | Pharmaceutical composition | |
EG24075A (en) | Pharmaceutical suspension comprising nevirapine hemihydrate | |
ZA98300B (en) | Pharmaceutical compounds | |
GB9717770D0 (en) | Pharmaceutical composition | |
GB9706376D0 (en) | Novel pharmaceutical | |
GB2321190B (en) | Pharmaceutical composition | |
GB9726781D0 (en) | Pharmaceutical composition | |
IL120319A0 (en) | Pharmaceutical preparation | |
CA82556S (en) | Capsule | |
GB9723472D0 (en) | Suspension means | |
ZA981391B (en) | Pharmaceutical composition | |
GB9710632D0 (en) | Pharmaceutical composition |